The Quantellect read.As of Nov 20, 2026, 10 active firms cover Vera Therapeutics Inc: 8 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $34.00 to $91.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $71.56 sits 167% above the current $26.75. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.24 next quarter toward $-3.92 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy880%
Neutral220%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$71.56
+167.5% upside
Average target across 9 active firms as of Nov 20, 2026 vs $26.75 current
Highest Target$91.00
Average Target$71.56
Lowest Target$34.00
Detailed analyst forecasts for VERA
Showing 1–9 of 9 named analysts shown · 10 active firms in the rating projection
As of Nov 20, 2026, 8 of 10 active firms rate VERA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VERA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.24
Range $-1.39 – $-1.06 · 4 analysts · -27% YoY
Next period, 4 analysts expect Vera Therapeutics Inc to earn $-1.24 a share (range $-1.39 – $-1.06), versus $-1.69 a year earlier. Full-year consensus is $-5.95, growing to $-3.92 the year after.
REVENUE · NEXT QUARTER
$40.2M
Range $33.2M – $46.9M · 4 analysts
Revenue is expected to reach $40.2M (range $33.2M – $46.9M). Full-year consensus is $31.2M, rising to $257.6M next year.
Top analysts covering Vera Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VERA.
#1
Laura Chico
Wedbush · Rank #55
Neutral
$34.00+27.1% to target
Overall win rate
46%
+ Follow
#2
Paul Choi
Goldman Sachs · Rank #110
Buy
$80.00+199.1% to target
Overall win rate
52%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Buy
No targeton VERA
Overall win rate
48%
+ Follow
#4
Arthur He
HC Wainwright & Co. · Rank #198
Buy
$90.00+236.4% to target
Overall win rate
50%
+ Follow
#5
Vamil Divan
Guggenheim · Rank #211
Buy
$66.00+146.7% to target
Overall win rate
48%
+ Follow
VERA stock forecast FAQ
What is VERA's average 12-month price target?+
The 9 active firms with a live target average $71.56 for Vera Therapeutics Inc over the next 12 months, ranging from a $91.00 high to a $34.00 low, as of Nov 20, 2026.
Is VERA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 20, 2026, 8 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VERA?+
The Street-high target is $91.00 (Evercore ISI Group), and the Street-low is $34.00 (Leerink Partners). The average of all 9 active-firm targets is $71.56.
How many active Wall Street firms cover VERA?+
10 active firms have a recognized rating on Vera Therapeutics Inc as of Nov 20, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VERA?+
Among analysts who currently cover VERA, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Neutral with a $34.00 target.
What is Vera Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.24 per share (range $-1.39 – $-1.06) across 4 analysts. Full-year EPS is projected at $-5.95, rising to $-3.92 the following year.
How much revenue is Vera Therapeutics Inc expected to report next quarter?+
Consensus revenue is $40.2M (range $33.2M – $46.9M). Full-year revenue is projected at $31.2M, growing to $257.6M next year.
Have analysts been upgrading or downgrading VERA lately?+
As of Nov 20, 2026, 8 of 10 active firms rate VERA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VERA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.